Dr. Kevin Fahey Appointed to illumiSonics Board of Directors

February 10, 2021

illumiSonics Inc., is a medical tissue imaging company. Today they announced the appointment of Kevin Fahey, Ph.D., to the Board of Directors. The company has taken this action in anticipation of its growth and the commercial introduction of its proprietary Photo Acoustic Remote Sensing (PARS) tissue imaging platform.

Dr. Kevin Fahey brings new skills and will help strengthen the board of directors.

“Dr. Fahey brings commercial imaging domain expertise and industry-specific relationships to fully enable the power and unique capabilities of PARS as we fundamentally change the way the world looks at living tissue,” said Rocky Ganske CEO.

“PARS brings all of the valuable imaging of traditional photoacoustics, uniquely without the need for an interface. This capability opens several clinical applications not possible today with any other commercial imaging technology. We believe this creates a number of product and partnering opportunities for illumiSonics, and I am looking forward to participating,” said Dr. Fahey.

Dr. Fahey held executive positions at Xradia (acquired by ZEISS) and FEI (acquired by ThermoFisher), and at both large and small companies. In every case, he drove dramatic growth, creating new business lines and implementing integrated sales and marketing channels that drove rapid increases in sales. Dr. Fahey holds a Ph.D. in Materials Science and Engineering from Stanford University and a B.S. in Physics from the Massachusetts Institute of Technology.

illumiSonics’ proprietary PARS photoacoustic remote sensing technology is a revolution in optical imaging. Like traditional photoacoustic imaging, PARS measures optical absorption and is capable of providing functional and molecular imaging of anything that can absorb light. Traditional photoacoustic imaging has been constrained by the need to have contact with targeted tissues, the size of transducers and an inability to easily integrate with other optical imaging techniques. PARS is the first fully optical, non-contact photoacoustic imaging technology. This allows PARS to maintain all of the advantages of photoacoustic imaging while addressing its shortcomings, which provides incredible flexibility in how it can be deployed.

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution